PTI - Proteostasis Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.0000
-0.0100 (-0.99%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.0100
Open1.0000
Bid0.9702 x 4000
Ask1.0100 x 800
Day's Range0.9701 - 1.0100
52 Week Range0.9100 - 10.3800
Volume379,496
Avg. Volume2,197,476
Market Cap51.099M
Beta (3Y Monthly)-1.82
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire12 days ago

    Proteostasis Therapeutics Receives Orphan Drug Designation in the EU for PTI-428 for the Treatment of Cystic Fibrosis

    BOSTON, June 4, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that the European Commission (EC) has granted orphan drug designation (ODD) to PTI-428 for the treatment of cystic fibrosis. PTI-428 is the Company's proprietary cystic fibrosis transmembrane conductance regulator (CFTR) amplifier that is currently in clinical development.

  • PR Newswire13 days ago

    Proteostasis Therapeutics Announces Presentations and Hosts Educational Symposium at the 42nd European Cystic Fibrosis Conference

    BOSTON , June 3, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to ...

  • PR Newswirelast month

    Proteostasis Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference

    BOSTON, May 15, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Proteostasis management will present at the 2019 RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 9:00 a.m. ET at the InterContinental New York Barclay. A live audio webcast of the RBC Capital Markets Global Healthcare Conference presentation will be available on the Investor Events page in the Investors & Media section of the Company's website, www.proteostasis.com. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing.

  • PR Newswirelast month

    Proteostasis Therapeutics Appoints Dr. Badrul Chowdhury, Former FDA Director of Pulmonology, Allergy, and Rheumatology, to Board of Directors

    BOSTON, May 13, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Badrul A. Chowdhury, M.D., Ph.D., has been appointed to the Company's Board of Directors. Dr. Chowdhury is Senior Vice President and Chief Physician-Scientist, Respiratory Inflammation and Autoimmunity (RIA) Late Stage, R&D Biopharmaceuticals, at AstraZeneca.  He was previously Director of the Division of Pulmonary, Allergy, and Rheumatology Products at the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER).

  • PR Newswirelast month

    Proteostasis Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

    BOSTON, May 8, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced financial results for the first quarter ended March 31, 2019 and provided a corporate update. "During the first quarter, we reported a compelling safety and efficacy data set from our 14-day studies, which led us to prioritize the clinical development of our proprietary combination cystic fibrosis transmembrane conductance regulator (CFTR) modulators," said Meenu Chhabra, President and Chief Executive Officer of Proteostasis Therapeutics.

  • PR Newswire3 months ago

    Proteostasis Therapeutics Announces Broad New Dataset from Proprietary Combination and Add-On CFTR Modulator Studies in Cystic Fibrosis Patients

    Greatest ppFEV1 Improvement Shown in High Dose Triplet with Mean Absolute Improvement in ppFEV1 of 8 Percentage Points at 14 Days Compared to Placebo (p All Combinations Studied Were Well-Tolerated, Including ...

  • PR Newswire3 months ago

    Proteostasis Therapeutics Appoints David Arkowitz to Board of Directors

    BOSTON, March 7, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that David Arkowitz has been appointed to the Company's Board of Directors. Mr. Arkowitz is the Chief Financial Officer (CFO) and Treasurer of Flexion Therapeutics, a publicly traded, commercial stage biotechnology company. Prior to joining Flexion, Mr. Arkowitz served as Chief Operating Officer and CFO at Visterra, a biotechnology company which was acquired by Otsuka Pharmaceutical Co., where he led the finance, business development, corporate planning and other functions.

  • PR Newswire4 months ago

    Proteostasis Selected to Join European Consortium to Pioneer Personalized Medicine in Cystic Fibrosis

    BOSTON, Feb. 27, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced it has been invited to join the HIT-CF Europe, a pan European strategic initiative which seeks to validate a personalized therapy approach for CF patients with extremely rare genetic mutations. HIT-CF is a consortium of researchers, doctors, pharmaceutical companies and patient representatives, which aims to provide better treatment for people with CF.

  • GlobeNewswire4 months ago

    Detailed Research: Economic Perspectives on Novartis AG, Proteostasis Therapeutics, Williams-Sonoma, Magna International, YRC Worldwide, and Delek Logistics Partners — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire4 months ago

    Proteostasis Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    BOSTON, Feb. 20, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Marija Zecevic, Ph.D., the Company's Chief Commercial Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 1:00 p.m. ET at the Lotte New York Palace. A live audio webcast of the SVB Leerink Global Healthcare Conference presentation will be available on the Investor Events page in the Investors & Media section of the Company's website, www.proteostasis.com. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing.

  • ACCESSWIRE4 months ago

    Biotech Plays in the News You Should Know

    HENDERSON, NV / ACCESSWIRE / February 12, 2019 / Below are several companies in the biotech space that are making news and drawing investor interest. These companies have the potential to make investors ...

  • ACCESSWIRE4 months ago

    Biotech Stocks Set to Pop

    HENDERSON, NV / ACCESSWIRE / February 7, 2019 / Biotech stocks are what growth investors thrive on. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the ...

  • ACCESSWIRE4 months ago

    4 Biotech Stocks Making Moves on Wednesday (2/6/19)

    Premier Health Group (OTC:PHGRF) (CSE:PHGI), Pulmatrix Inc (PULM), MacroGenics Inc (MGNX), and Proteostasis Therapeutics Inc (PTI) represent four biotech companies creating nuanced approaches to further the advancement of modern medicine. The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments which demonstrate Premier's dedication to the betterment of the biotech industry, and more importantly, to consumers looking to enhance their quality of life. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced at the tail-end of last month that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.

  • PR Newswire4 months ago

    Proteostasis Therapeutics Appoints Emmanuel Dulac and Kim Drapkin to Board of Directors

    BOSTON, Feb. 6, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Emmanuel Dulac, PharmD, Ph.D., and Kim Cobleigh Drapkin, CPA, have been appointed to the Company's Board of Directors. Dr. Dulac joined Alnylam Pharmaceuticals in August 2016 as Chief Commercial Officer to establish the company's global commercial organization.

  • ACCESSWIRE6 months ago

    These 4 Biotech Stocks Are Raising Eyebrows

    CORAL GABLES, FL / ACCESSWIRE / December 21, 2018 / The biotech industry is based on a framework made up of cunning edge medical technologies designed with the patient's best interests at heart. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Proteostasis Therapeutics, Inc (PTI), Alta Mesa Resources, Inc (AMR), and Stemline Therapeutics, Inc (STML) are 4 biotech stocks worth taking a look at. Premier Health Group (OTC:PHGRF) (CSE:PHGI), as a company, recognizes the importance of meeting the demands and needs of its 100,000, and growing, active patient network.

  • PR Newswire6 months ago

    Proteostasis Therapeutics Provides Clinical Enrollment Update

    BOSTON, Dec. 20, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today provided a clinical enrollment update.  The Company, while remaining blinded to data from the first cohort, now expects to report complete efficacy and safety data from the Phase 1, randomized, double-blind, placebo-controlled study of its proprietary combination therapy triplet (PTI-808, PTI-801, and PTI-428) and from the high-dose doublet study in subjects with CF in the first quarter of 2019. The Company previously planned to report preliminary results from the triplet study by dose cohort as each dose cohort was completed, beginning with a low-dose cohort.

  • PR Newswire6 months ago

    Proteostasis Therapeutics Announces Global License Agreement with Genentech

    BOSTON, Dec. 17, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced a worldwide, exclusive license agreement with Genentech, a member of the Roche Group, for rights to potential therapeutic small molecule modulators of an undisclosed target within the proteostasis network.  The agreement does not include cystic fibrosis transmembrane conductance regulator (CFTR) modulators and is unrelated to PTI's investigational medicines or other ongoing research programs in cystic fibrosis. The proteostasis network consists of more than 1,000 proteins organized into pathways that can be regulated or targeted by drugs.

  • PR Newswire7 months ago

    Proteostasis Therapeutics to Participate in Upcoming Investor Conferences

    BOSTON , Nov. 21, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to ...

  • PR Newswire8 months ago

    Proteostasis Therapeutics Prices Public Offering of Common Stock

    BOSTON, Oct. 23, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today that it has priced an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $6.75 per share. The gross proceeds to Proteostasis from the offering, before underwriting discounts and commissions and offering costs, are expected to be approximately $74.3 million.  Proteostasis has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock. All of the shares to be sold in the offering are being sold by Proteostasis.

  • PR Newswire8 months ago

    Proteostasis Therapeutics Announces Proposed Public Offering of Common Stock

    BOSTON, Oct. 22, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today that it intends to offer and sell, subject to market and other conditions, 9,000,000 shares of its common stock in an underwritten public offering. As part of this offering, Proteostasis intends to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock.  All of the shares to be sold in the offering are to be sold by Proteostasis. Leerink Partners, Piper Jaffray & Co. and Cantor Fitzgerald & Co. are acting as joint book-running managers for the offering.

  • ACCESSWIRE8 months ago

    Today’s Research Reports on Stocks to Watch: Proteostasis Therapeutics and Endocyte

    NEW YORK, NY / ACCESSWIRE / October 19, 2018 / Shares of biotech stocks Proteostasis Therapeutics and Endocyte were seeing big gains on different exciting announcements. Proteostasis announced encouraging preliminary results while traders learned that Endocyte will be purchased by Novartis for $2.1 billion. Proteostasis Therapeutics, Inc. shares closed up 447.62% on Thursday on skyrocket volume of about 94 million shares.

  • PR Newswire8 months ago

    Proteostasis Therapeutics Announces Positive Preliminary Results from Proprietary Doublet in Cystic Fibrosis Patients

    BOSTON, Oct. 17, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced positive preliminary results from three doublet cohorts of the Company's ongoing Phase 1, randomized, double-blind, placebo-controlled studies of the Company's proprietary combination therapy doublet, PTI-808 and PTI-801, and an enrollment update from the triplet, PTI-808, PTI-801, and PTI-428, in subjects with cystic fibrosis.

  • PR Newswire9 months ago

    Proteostasis Therapeutics to Present at the Cantor Global Healthcare Conference

    BOSTON, Sept. 27, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Marija Zecevic, Ph.D., the Company's Chief Operating Officer, will present at the Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 3:25 p.m. ET at the InterContinental New York Barclay. A live audio webcast of the Cantor Global Healthcare Conference presentation will be available on the Investor Events page in the Investors & Media section of the Company's website, www.proteostasis.com. A replay of the webcast will be available on the Company's website following the presentation.